Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Non-Current Deferred Tax Liability of $36.7 million for Q1 2026, down 49.73% year-over-year from $73.0 million in Q1 2025, and little changed quarter-over-quarter from $36.6 million in Q4 2025.
Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Non-Current Deferred Tax Liability for 6 consecutive years, with $36.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 49.73% year-over-year to $36.7 million; the TTM figure through Mar 2026 stood at $36.7 million (down 49.73% YoY), while the FY2025 annual figure was $36.6 million, down 63.85% from the prior year.
- Non-Current Deferred Tax Liability steadied at $36.7 million in Q1 2026 per VRNO's latest filing, from $36.6 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $259.3 million in Q2 2022 and bottomed at $2.7 million in Q1 2022.
- Historically, Non-Current Deferred Tax Liability has averaged $140.2 million across 5 years, with a median of $174.8 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 26219.88% — and 2025, when it tumbled 63.85%.
- Verano Holdings' Non-Current Deferred Tax Liability stood at $209.0 million in 2022, then fell by 12.8% to $182.2 million in 2023, then tumbled by 44.38% to $101.4 million in 2024, then sank by 63.85% to $36.6 million in 2025, then advanced by 0.11% to $36.7 million in 2026.
- Business Quant data shows VRNO's Non-Current Deferred Tax Liability at $36.7 million in Q1 2026, $36.6 million in Q4 2025, and $71.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Verano Holdings | 450.50 Mn | 365.31 Mn | 99.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.41 Mn |
| Jun 30, 2026 | 43.41 Mn |
| Mar 31, 2026 | 36.69 Mn |
| Mar 31, 2026 | 36.69 Mn |
| Dec 31, 2025 | 36.64 Mn |
| Dec 31, 2025 | 36.64 Mn |
| Sep 30, 2025 | 71.02 Mn |
| Sep 30, 2025 | 71.02 Mn |
| Jun 30, 2025 | 72.37 Mn |
| Jun 30, 2025 | 72.37 Mn |
| Mar 31, 2025 | 72.98 Mn |
| Mar 31, 2025 | 72.98 Mn |
| Dec 31, 2024 | 101.36 Mn |
| Dec 31, 2024 | 101.36 Mn |
| Sep 30, 2024 | 168.16 Mn |
| Sep 30, 2024 | 168.16 Mn |
| Jun 30, 2024 | 174.79 Mn |
| Jun 30, 2024 | 174.79 Mn |
| Mar 31, 2024 | 180.25 Mn |
| Mar 31, 2024 | 180.25 Mn |